

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned “**Version With Markings to Show Changes Made**”.

AJZ:jmm

FILED: 3 AUGUST 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 4-6, 8-13 and 15-16 have been amended as follows:

4. (Amended) Combination according to ~~one of the preceding claims 1~~, whereby the cyclodextrin is a β -cyclodextrin.

5. (Amended) Combination according to ~~one of the preceding claims 1~~, whereby the cyclodextrin and the gestagen

are present with β -cyclodextrin in a complex of 1:n (gestagen : cyclodextrin, $n \geq 1$), and

are present with γ -cyclodextrin in a complex of 1:n ($n \geq 1$) (gestagen : cyclodextrin).

6. (Amended) Combination according to ~~one of the preceding claims 1~~ as a pharmaceutical agent.

8. (Amended) Combination according to claim 6 ~~or 7~~ for the production of a pharmaceutical agent for treating menopausal symptoms.

9. (Amended) Combination according to ~~one of the preceding claims 1 to 5~~ for birth control.

10. (Amended) Pharmaceutical agent or pharmaceutical preparation that contains a combination according to ~~one of the preceding claims 1~~ with pharmaceutically compatible adjuvants and vehicles.

11. (Amended) Pharmaceutical agent or pharmaceutical preparation that contains a combination according to ~~one of the preceding claims 1~~ for peroral, oral, parenteral, transdermal, pulmonary, nasal, rectal, vaginal or intrauterine use.

12. (Amended) Use of a combination according to ~~one of the preceding claims 1 to 9~~ for the production of a medication for treating premenstrual symptoms, such as headaches, depression, water retention and mastodynia.

13. (Amended) Process for birth control with administration of a combination according to ~~one of claims 1 to 9~~.

15. (Amended) Process for complexing a gestagen according to ~~one of claims 1 and 2~~ and a β -cyclodextrin or γ -cyclodextrin while being triturated as a dry mixture or by precipitation reaction, preferably co-precipitation.

16. (Amended) Process for direct pelletizing of a gestagen complex according to one of claims 1 and 2 with a β -cyclodextrin or γ -cyclodextrin with the addition of pharmaceutically compatible adjuvants.